RT Journal Article
SR Electronic
T1 Distinct pancreatic and neuronal Lung Carcinoid molecular subtypes revealed by integrative omic analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.27.21260865
DO 10.1101/2021.07.27.21260865
A1 Domingo-Sabugo, Clara
A1 Willis-Owen, Saffron A.G.
A1 Mandal, Amit
A1 Nastase, Anca
A1 Dwyer, Sarah
A1 Brambilla, Cecilia
A1 Gálvez, José Héctor
A1 Zhuang, Qinwei
A1 Popat, Sanjay
A1 Eveleigh, Robert
A1 Munter, Markus
A1 Lim, Eric
A1 Nicholson, Andrew G.
A1 Lathrop, Mark
A1 Cookson, William O.C.
A1 Moffatt, Miriam F.
YR 2021
UL http://medrxiv.org/content/early/2021/07/30/2021.07.27.21260865.abstract
AB Lung Carcinoids (L-CDs) are uncommon low-grade neuroendocrine tumours that are only recently becoming characterised at the molecular level. Notably data on the molecular events that precipitate altered gene expression programmes are very limited. Here we have identified two discrete L-CD subtypes from transcriptomic and whole-genome DNA methylation data, and comprehensively defined their molecular profiles using Whole-Exome Sequencing (WES) and Single Nucleotide Polymorphism (SNP) genotyping. Subtype (Group) 1 features upregulation of neuronal markers (L-CD-NeU) and is characterised by focal spindle cell morphology, peripheral location (71%), high mutational load (P=3.4×10−4), recurrent copy number alterations and is enriched for Atypical Lung Carcinoids. Group 2 (L-CD-PanC) are centrally located and feature upregulation of pancreatic and metabolic pathway genes concordant with promoter hypomethylation of beta cell and genes related to insulin secretion (P<1×10−6). L-CD-NeU tumours harbour mutations in chromatin remodelling and in SWI/SNF complex members, while L-CD-PanC tumours show aflatoxin mutational signatures and significant DNA methylation loss genome-wide, particularly enriched in repetitive elements (P<2.2 × 10−16). Our findings provide novel insights into the distinct mechanisms of epigenetic dysregulation in these lung malignancies, potentially opening new avenues for biomarker selection and treatment in L-CD patients.Competing Interest StatementA.N. reports personal fees from Merck, Boehringer Ingelheim, Novartis, Astra Zeneca, Bristol Myer Squib, Roche, Abbvie and Oncologica, as well as grants and personal fees from Pfizer outside the submitted work. E.L. reports personal fees from Glaxo Smith Kline, Pfizer, Novartis, Covidien, Roche, Lily Oncology, Boehringer Ingelheim, Medela, Astra Zeneca and Ethicon; Grants and personal fees from ScreenCell; Grants from Clearbridge Biomedics, Illumina and Guardant Health, outside the submitted work. In addition, E.L. has patents P52435GB and P57988GB issued to Imperial Innovations, is the Director of lung screening at the Cromwell Hospital, and is CI for both VIOLET NIHR HTA (13/04/03) and MARS 2 NIHR HTA (15/188/31). S.P. reports personal fees from BMS, Roche, Takeda, AstraZeneca, Pfizer, MSD, EMD, Serono, Guardant Health, Abbvie, Boehringer Ingelheim, OncLive, Medscape, Incyte, Paradox Pharmaceuticals and Eli Lilly outside the submitted work. The other authors declare no competing interests.Funding StatementWe thank the patients for participating to our study. We also thank Dr. Alain Pacis and Paul Stretenowich for their help with the analysis of WGBS data. This study was supported by the Asmarley Trust and by the Wellcome Trust. Sample collection for this study was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust. The funding sources had no role in study design, collection, analysis and interpretation of the data, or in the writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study methodologies followed the standards set by the Declaration of Helsinki and were conducted under approval by the Royal Brompton and Harefield Research Ethics Committee (RBH) NIHR BRU Advanced Lung Disease Biobank (NRES reference 10/H0504/9) and Brompton and Harefield NHS Trust Diagnostic Tissue Bank (NRES reference 10/H0504/29) [Discovery], and the Royal Brompton and Harefield Ethics Committee (REC reference number LREC 02-261) [Replication]. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenotyping and sequencing data generated during the current study will be submitted at the European Genome-Phenome Archive (EGA) (https://ega-archive.org/) under accession code: EGAS00001005473.